Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Pharmacological modulation of metabotropic glutamate receptor subtype 5 and 7 impairs extinction of social fear in a time-point-dependent manner.

Slattery DA, Neumann ID, Flor PJ, Zoicas I.

Behav Brain Res. 2017 Jun 15;328:57-61. doi: 10.1016/j.bbr.2017.04.010. Epub 2017 Apr 7.

PMID:
28392321
2.

Individual differences in stress vulnerability: The role of gut pathobionts in stress-induced colitis.

Langgartner D, Peterlik D, Foertsch S, Füchsl AM, Brokmann P, Flor PJ, Shen Z, Fox JG, Uschold-Schmidt N, Lowry CA, Reber SO.

Brain Behav Immun. 2017 Aug;64:23-32. doi: 10.1016/j.bbi.2016.12.019. Epub 2016 Dec 21.

PMID:
28012830
3.

Type-7 metabotropic glutamate receptors negatively regulate α1-adrenergic receptor signalling.

Iacovelli L, Di Menna L, Peterlik D, Stangl C, Orlando R, Molinaro G, De Blasi A, Bruno V, Battaglia G, Flor PJ, Uschold-Schmidt N, Nicoletti F.

Neuropharmacology. 2017 Feb;113(Pt A):343-353. doi: 10.1016/j.neuropharm.2016.10.018. Epub 2016 Oct 18.

PMID:
27769854
4.

Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences.

Peterlik D, Stangl C, Bauer A, Bludau A, Keller J, Grabski D, Killian T, Schmidt D, Zajicek F, Jaeschke G, Lindemann L, Reber SO, Flor PJ, Uschold-Schmidt N.

Brain Behav Immun. 2017 Jan;59:79-92. doi: 10.1016/j.bbi.2016.08.007. Epub 2016 Aug 11.

PMID:
27524668
5.

The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders.

Peterlik D, Flor PJ, Uschold-Schmidt N.

Curr Neuropharmacol. 2016;14(5):514-39. Review.

6.

Relief from detrimental consequences of chronic psychosocial stress in mice deficient for the metabotropic glutamate receptor subtype 7.

Peterlik D, Stangl C, Bludau A, Grabski D, Strasser R, Schmidt D, Flor PJ, Uschold-Schmidt N.

Neuropharmacology. 2017 Mar 15;115:139-148. doi: 10.1016/j.neuropharm.2016.04.036. Epub 2016 May 14.

PMID:
27188844
7.

Metabotropic Glutamate Receptor Subtype 7 in the Bed Nucleus of the Stria Terminalis is Essential for Intermale Aggression.

Masugi-Tokita M, Flor PJ, Kawata M.

Neuropsychopharmacology. 2016 Feb;41(3):726-35. doi: 10.1038/npp.2015.198. Epub 2015 Jul 7.

8.

AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.

Vranesic I, Ofner S, Flor PJ, Bilbe G, Bouhelal R, Enz A, Desrayaud S, McAllister K, Kuhn R, Gasparini F.

Bioorg Med Chem. 2014 Nov 1;22(21):5790-803. doi: 10.1016/j.bmc.2014.09.033. Epub 2014 Sep 20.

PMID:
25316499
9.

Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior.

Gee CE, Peterlik D, Neuhäuser C, Bouhelal R, Kaupmann K, Laue G, Uschold-Schmidt N, Feuerbach D, Zimmermann K, Ofner S, Cryan JF, van der Putten H, Fendt M, Vranesic I, Glatthar R, Flor PJ.

J Biol Chem. 2014 Apr 18;289(16):10975-87. doi: 10.1074/jbc.M113.542654. Epub 2014 Mar 4.

10.

Differential roles of mGlu(7) and mGlu(8) in amygdala-dependent behavior and physiology.

Fendt M, Imobersteg S, Peterlik D, Chaperon F, Mattes C, Wittmann C, Olpe HR, Mosbacher J, Vranesic I, van der Putten H, McAllister KH, Flor PJ, Gee CE.

Neuropharmacology. 2013 Sep;72:215-23. doi: 10.1016/j.neuropharm.2013.04.052. Epub 2013 May 7.

PMID:
23664812
11.

Adult siRNA-induced knockdown of mGlu7 receptors reduces anxiety in the mouse.

O'Connor RM, Thakker DR, Schmutz M, van der Putten H, Hoyer D, Flor PJ, Cryan JF.

Neuropharmacology. 2013 Sep;72:66-73. doi: 10.1016/j.neuropharm.2013.03.028. Epub 2013 Apr 17.

PMID:
23603202
12.

Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice.

Peters S, Slattery DA, Flor PJ, Neumann ID, Reber SO.

Addict Biol. 2013 Jan;18(1):66-77. doi: 10.1111/adb.12001. Epub 2012 Nov 6.

PMID:
23126471
13.

Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7.

Ullmer C, Zoffmann S, Bohrmann B, Matile H, Lindemann L, Flor P, Malherbe P.

Br J Pharmacol. 2012 Dec;167(7):1448-66. doi: 10.1111/j.1476-5381.2012.02090.x.

14.

Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs.

Flor PJ, Acher FC.

Biochem Pharmacol. 2012 Aug 15;84(4):414-24. doi: 10.1016/j.bcp.2012.04.013. Epub 2012 Apr 24. Review.

PMID:
22554564
15.

Pharmacological interference with metabotropic glutamate receptor subtype 7 but not subtype 5 differentially affects within- and between-session extinction of Pavlovian conditioned fear.

Toth I, Dietz M, Peterlik D, Huber SE, Fendt M, Neumann ID, Flor PJ, Slattery DA.

Neuropharmacology. 2012 Mar;62(4):1619-26. doi: 10.1016/j.neuropharm.2011.10.021. Epub 2011 Nov 10.

PMID:
22079159
16.

Pharmacological modulation of mGluR7 with AMN082 and MMPIP exerts specific influences on alcohol consumption and preference in rats.

Bahi A, Fizia K, Dietz M, Gasparini F, Flor PJ.

Addict Biol. 2012 Mar;17(2):235-47. doi: 10.1111/j.1369-1600.2010.00310.x. Epub 2011 Mar 11.

PMID:
21392179
17.

Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues.

Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF.

Pharmacol Rev. 2011 Mar;63(1):35-58. doi: 10.1124/pr.110.004036. Epub 2011 Jan 12. Review.

PMID:
21228260
18.

Metabotropic glutamate receptor 7: at the interface of cognition and emotion.

O'Connor RM, Finger BC, Flor PJ, Cryan JF.

Eur J Pharmacol. 2010 Aug 10;639(1-3):123-31. doi: 10.1016/j.ejphar.2010.02.059. Epub 2010 Apr 2. Review.

PMID:
20371242
19.

Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.

Greco B, Lopez S, van der Putten H, Flor PJ, Amalric M.

J Pharmacol Exp Ther. 2010 Mar;332(3):1064-71. doi: 10.1124/jpet.109.162115. Epub 2009 Nov 25.

PMID:
19940105
20.

Selective activation of metabotropic G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission.

Stachowicz K, Brañski P, Kłak K, van der Putten H, Cryan JF, Flor PJ, Andrzej P.

Behav Pharmacol. 2008 Sep;19(5-6):597-603. doi: 10.1097/FBP.0b013e32830cd839.

PMID:
18690114
21.

Amygdaloid metabotropic glutamate receptor subtype 7 is involved in the acquisition of conditioned fear.

Siegl S, Flor PJ, Fendt M.

Neuroreport. 2008 Jul 16;19(11):1147-50. doi: 10.1097/WNR.0b013e328307f295.

PMID:
18596617
22.

mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity.

Fendt M, Schmid S, Thakker DR, Jacobson LH, Yamamoto R, Mitsukawa K, Maier R, Natt F, Hüsken D, Kelly PH, McAllister KH, Hoyer D, van der Putten H, Cryan JF, Flor PJ.

Mol Psychiatry. 2008 Oct;13(10):970-9. Epub 2007 Aug 21.

PMID:
17712315
23.

Activation of the mGlu7 receptor elicits antidepressant-like effects in mice.

Palucha A, Klak K, Branski P, van der Putten H, Flor PJ, Pilc A.

Psychopharmacology (Berl). 2007 Nov;194(4):555-62. Epub 2007 Jul 12.

PMID:
17622518
24.

Functional role of mGluR1 and mGluR4 in pilocarpine-induced temporal lobe epilepsy.

Pitsch J, Schoch S, Gueler N, Flor PJ, van der Putten H, Becker AJ.

Neurobiol Dis. 2007 Jun;26(3):623-33. Epub 2007 Mar 16.

PMID:
17446080
25.

Night blindness-associated mutations in the ligand-binding, cysteine-rich, and intracellular domains of the metabotropic glutamate receptor 6 abolish protein trafficking.

Zeitz C, Forster U, Neidhardt J, Feil S, Kälin S, Leifert D, Flor PJ, Berger W.

Hum Mutat. 2007 Aug;28(8):771-80.

PMID:
17405131
26.

Synthesis and preliminary pharmacological evaluation of the four stereoisomers of (2S)-2-(2'-phosphono-3'-phenylcyclopropyl)glycine, the first class of 3'-substituted trans C1'-2'-2-(2'-phosphonocyclopropyl)glycines.

Marinozzi M, Serpi M, Amori L, Gavilan Diaz M, Costantino G, Meyer U, Flor PJ, Gasparini F, Heckendorn R, Kuhn R, Giorgi G, Hermit MB, Thomsen C, Pellicciari R.

Bioorg Med Chem. 2007 May 1;15(9):3161-70. Epub 2007 Feb 22.

PMID:
17350267
27.

A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo.

Mitsukawa K, Yamamoto R, Ofner S, Nozulak J, Pescott O, Lukic S, Stoehr N, Mombereau C, Kuhn R, McAllister KH, van der Putten H, Cryan JF, Flor PJ.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18712-7. Epub 2005 Dec 9.

28.

Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders.

Mitsukawa K, Mombereau C, Lötscher E, Uzunov DP, van der Putten H, Flor PJ, Cryan JF.

Neuropsychopharmacology. 2006 Jun;31(6):1112-22.

29.

(-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection.

Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, Kuhn R, Nicoletti F, Flor PJ.

Neuropharmacology. 2003 Dec;45(7):895-906.

PMID:
14573382
30.

Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7.

Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, van Der Putten H.

Eur J Neurosci. 2003 Jun;17(11):2409-17.

PMID:
12814372
31.

Neuroprotective activity of metabotropic glutamate receptor ligands.

Flor PJ, Battaglia G, Nicoletti F, Gasparini F, Bruno V.

Adv Exp Med Biol. 2002;513:197-223. Review.

PMID:
12575822
32.

In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: review article.

Kuhn R, Pagano A, Stoehr N, Vranesic I, Flor PJ, Lingenhöhl K, Spooren W, Gentsch C, Vassout A, Pilc A, Gasparini F.

Amino Acids. 2002;23(1-3):207-11. Review.

PMID:
12373539
33.

[(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5.

Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhöhl K, Müller H, Munk VC, Omilusik K, Stierlin C, Stoehr N, Vranesic I, Kuhn R.

Bioorg Med Chem Lett. 2002 Feb 11;12(3):407-9.

PMID:
11814808
34.

Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7.

Sansig G, Bushell TJ, Clarke VR, Rozov A, Burnashev N, Portet C, Gasparini F, Schmutz M, Klebs K, Shigemoto R, Flor PJ, Kuhn R, Knoepfel T, Schroeder M, Hampson DR, Collett VJ, Zhang C, Duvoisin RM, Collingridge GL, van Der Putten H.

J Neurosci. 2001 Nov 15;21(22):8734-45.

35.

Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.

Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, Nicoletti F.

J Cereb Blood Flow Metab. 2001 Sep;21(9):1013-33. Review.

PMID:
11524608
36.

Discovery and characterization of non-competitive antagonists of group I metabotropic glutamate receptors.

Gasparini F, Floersheim P, Flor PJ, Heinrich M, Inderbitzin W, Ott D, Pagano A, Stierlin C, Stoehr N, Vranesic I, Kuhn R.

Farmaco. 2001 Jan-Feb;56(1-2):95-9. Review.

PMID:
11347975
37.

An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors.

Bruno V, Battaglia G, Copani A, Cespédes VM, Galindo MF, Ceña V, Sánchez-Prieto J, Gasparini F, Kuhn R, Flor PJ, Nicoletti F.

Eur J Neurosci. 2001 Apr;13(8):1469-78.

PMID:
11328342
38.

Chiral resolution, pharmacological characterization, and receptor docking of the noncompetitive mGlu1 receptor antagonist (+/-)-2-hydroxyimino- 1a, 2-dihydro-1H-7-oxacyclopropa[b]naphthalene-7a-carboxylic acid ethyl ester.

Ott D, Floersheim P, Inderbitzin W, Stoehr N, Francotte E, Lecis G, Richert P, Rihs G, Flor PJ, Kuhn R, Gasparini F.

J Med Chem. 2000 Nov 16;43(23):4428-36.

PMID:
11087567
39.

Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain.

Walker K, Bowes M, Panesar M, Davis A, Gentry C, Kesingland A, Gasparini F, Spooren W, Stoehr N, Pagano A, Flor PJ, Vranesic I, Lingenhoehl K, Johnson EC, Varney M, Urban L, Kuhn R.

Neuropharmacology. 2001;40(1):1-9.

PMID:
11077065
40.

Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective.

Bruno V, Ksiazek I, Battaglia G, Lukic S, Leonhardt T, Sauer D, Gasparini F, Kuhn R, Nicoletti F, Flor PJ.

Neuropharmacology. 2000 Sep;39(12):2223-30.

PMID:
10974306
41.

Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death.

Bruno V, Battaglia G, Ksiazek I, van der Putten H, Catania MV, Giuffrida R, Lukic S, Leonhardt T, Inderbitzin W, Gasparini F, Kuhn R, Hampson DR, Nicoletti F, Flor PJ.

J Neurosci. 2000 Sep 1;20(17):6413-20.

42.

The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors.

Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezèau L, Carroll F, Pin JP, Cambria A, Vranesic I, Flor PJ, Gasparini F, Kuhn R.

J Biol Chem. 2000 Oct 27;275(43):33750-8.

43.
44.

(+)-4-phosphonophenylglycine (PPG) a new group III selective metabotropic glutamate receptor agonist.

Gasparini F, Inderbitzin W, Francotte E, Lecis G, Richert P, Dragic Z, Kuhn R, Flor PJ.

Bioorg Med Chem Lett. 2000 Jun 5;10(11):1241-4.

PMID:
10866390
45.

Distinct influence of the group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage.

Henrich-Noack P, Flor PJ, Sabelhaus CF, Prass K, Dirnagl U, Gasparini F, Sauter A, Rudin M, Reymann KG.

Neuropharmacology. 2000 Mar 3;39(5):911-7.

PMID:
10699457
46.

2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist.

Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Veliçelebi G, Kuhn R.

Neuropharmacology. 1999 Oct;38(10):1493-503.

PMID:
10530811
47.

SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5.

Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Veliçelebi G, Johnson EC.

J Pharmacol Exp Ther. 1999 Jul;290(1):170-81.

PMID:
10381773
48.

(R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo.

Gasparini F, Bruno V, Battaglia G, Lukic S, Leonhardt T, Inderbitzin W, Laurie D, Sommer B, Varney MA, Hess SD, Johnson EC, Kuhn R, Urwyler S, Sauer D, Portet C, Schmutz M, Nicoletti F, Flor PJ.

J Pharmacol Exp Ther. 1999 Jun;289(3):1678-87.

PMID:
10336568
49.

CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.

Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, Kuhn R.

Mol Pharmacol. 1999 Mar;55(3):453-61.

PMID:
10051528
50.

Functional coupling of a human retinal metabotropic glutamate receptor (hmGluR6) to bovine rod transducin and rat Go in an in vitro reconstitution system.

Weng K, Lu C, Daggett LP, Kuhn R, Flor PJ, Johnson EC, Robinson PR.

J Biol Chem. 1997 Dec 26;272(52):33100-4.

Supplemental Content

Loading ...
Support Center